The NCI-60 cell line set is likely the most molecularly profiled set of human tumor cell lines in the world. However, a critical missing component of previous analyses has been the inability to place the massive amounts of "-omic" data in the context of functional protein signaling networks, which often contain many of the drug targets for new targeted therapeutics.
INTRODUCTION
The NCI-60 cell lines are a set of human tumor cell lines collected by the National Cancer Institute (NCI) over the last twenty years to accomplish drug screening tests of more than 100,000 chemical compounds and natural extracts (1) . This panel represents the most common solid and soft tumors derived from 9 different tissues such as blood, lung, colon, kidney, breast, skin, prostate, ovary and central nervous system. The NCI-60 cell line set is used in laboratories throughout the world as in vitro tumor models thanks to their advantages of reproducibility, availability and representation of tumor site lineages. Most recently, the NCI-60 cell lines have been characterized by a number of high-throughput molecular profiling efforts through DNA mutations (2) , RNA (3), SNPs (4), miRNAs (5), metabolomic, proteomic (6) , and karyotyping (7) screens which have led to a better understanding of the biology of these cell lines, and an increased understanding concerning the relationships between therapeutic resistance/sensitivity and the underpinning biology. Many scientists are now focusing on protein-based analysis for these types of studies because of the proximity of the proteome to the mechanism of action of most therapeutics and their primary relationship to cellular biochemistry. Past efforts utilized techniques such as 2-dimensional PAGE, mass spectrometry based profiling and both antibody and protein microarrays (8) .
Reverse-Phase Protein microArray (RPPA) technology (9) , in particular, has been used to gain better insights into the expression profiles of the NCI-60 set due to its ability to quantitatively measure a large number of protein analytes at once with extremely high sensitivity, and was used to measure a subscribed set of proteins and phosphoproteins from the NCI-60 cell lines (6, 10) .
However, these past efforts have failed to systematically interrogate the signaling architecture of this important set using broad-scale, functional phosphoproteomic mapping within the context of a focused network-oriented approach. In our work described herein, we utilized RPPA to measure the activation/phosphorylation state of 135 key signaling proteins, and a total of nearly 200 protein endpoints (i.e. cleaved, phosphorylated, and/or total protein isoforms), involved in many aspects of tumorigenesis and metastatic progression and representing drug targets for a number of current and experimental therapeutics across the entire 60 lines that comprise the NCI-60 set. We aggregated these individual protein measurements in a systems-based, pathway-oriented manner that was then used to interrogate these pathway activity profiles more deeply within the context of the myriad of "-omic" measurements and coordinate enormous existing drug sensitivity data sets. This analysis uncovered new biochemical linkages between drug sensitivities, RNA, DNA, protein, phosphoprotein, and metabolomic profiles, and could provide a beginning step to more fully link drug sensitivity and "-omic"-based interconnections to a network-focused view of tumor biology.
MATERIALS AND METHODS

Protein Lysate Preparation
Three independent sets of the NCI-60 cell lines were obtained as frozen, non-viable cell pellets from the Developmental Therapeutics Program, National Cancer Institute (Frederick, MD) (N=180). The cell pellets were lysed in buffer containing T-PER reagent (Thermo-Fisher Scientific, Waltham, MA), 300mM NaCl, 1mM orthovanadate, 2mM Pefabloc (Roche, Basel, Switzerland), 5µg/ml aprotinin (Sigma, St. Louis, MO), 5µg/ml pepstatin A (Sigma, St. Louis, MO) and 5µg/ml leupeptin (Sigma, St. Louis, MO) and incubated on ice for 20 minutes. Samples were centrifuged at 9,300xg for 5 minutes, and the supernatant transferred to fresh tubes. Protein concentrations were measured using Coomassie protein assay reagent (Thermo Fisher Scientific, Waltham, MA). The lysates were then diluted for printing in extraction buffer containing 50% T-PER (Thermo Fisher Scientific, Waltham, MA), 47.5% 2xSDS (Invitrogen, Carlsbad, CA) and 2.5% β-mercaptoethanol (Thermo Fisher Scientific, Waltham, MA) to concentrations of 0.5µg/µl and 0.125µg/µl. RPPAs were constructed and analyzed as previously described (9) . Briefly, samples from the replicate sets of the 60 cell lines were printed in triplicate spots on nitrocellulose-coated glass slides (GRACE Bio-Labs, Bend, OR) using an Aushon 2470 arrayer equipped with 185-μm pins (Aushon Biosystems, Billerica, MA), according to the manufacturer's instructions. Reference standard lysates, comprised of HeLa + Pervanadate (BD, Franklin Lakes, NJ), Jurkat + Etoposide (Cell Signaling, Danvers, MA) and Jurkat + Calyculin A (Cell Signaling) cell lysates, were printed in 10-point dilution curves as procedural controls and as positive controls for antibody staining. Each reference standard curve was printed in triplicate at concentrations of 0.5μg/μl and 0.125μg/μl. A selected subset of the printed array slides were stained with Sypro Ruby Protein Blot Stain (Invitrogen, Carlsbad, CA) to estimate sample total protein concentration, and the remaining slides were stored desiccated at −20°C. Just prior to antibody staining, printed slides were treated with 1x
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ReBlot Mild Solution (Chemicon, Temecula, CA) for 15 minutes, washed 2x5 minutes with PBS (Invitrogen, Carlsbad, CA) and incubated for 1 hour in blocking solution (2% I-Block, (Applied Biosystems, Foster City, CA), 0.1% Tween-20 in PBS). Immunostaining was completed on an automated slide stainer using a catalyzed signal amplification kit (CSA kit, DAKO, Carpinteria, CA). The arrays were probed with a library of almost 200 antibodies against total, cleaved and phospho-protein endpoints (Supplementary Table S1 ). Primary antibody binding was detected using a biotinylated goat anti-rabbit IgG H+L (1:7500) (Vector Laboratories, Burlingame, CA) or rabbit anti-mouse IgG (1:10) (DAKO) followed by streptavidin-conjugated IRDye680 fluorophore. (LI-COR Biosciences, Lincoln, NE). Prior to use, primary antibodies were extensively validated for single band specificity by Western immunoblotting with complex cellular lysates. Negative control slides were incubated with secondary antibody only. All Sypro and immunostained slides were scanned using a Revolution 4550 scanner (Vidar Corp., Herndon, VA) and acquired images were 
Protein Pathway Activation Score Determination
Protein signaling pathway activation modules for AKT, mTOR, EGFR, IGF-1R, integrin, and apoptosis signaling were defined based on known biochemical linkages between the individual phosphoproteins quantitatively measured by RPPA. Pathway activation module scores were calculated by first scaling the relative intensity values within each endpoint to the sample with the highest value, resulting in values ranging from 1 to 0 that were designated as the "single endpoint score". Secondly, final pathway activation module scores for each sample were generated by summing the single individual phosphoprotein score for each endpoint component in a given module. These scores, referred to as an "overall module score" or "pathway activation score", represent the whole activation status of each of the six pathways under consideration for each cell line.
"-Omic" Network Analysis
We downloaded the following normalized datasets for the NCI-60 cell lines from CellMiner (11): mRNA expression measured using Affymetrix HG-U133, miRNA expression measured using Agilent Human miRNA microarray and OSU V3 chip, DNA copy number measured with OncoBAC DNA microarrays, and DNA mutation data. From the same source, we also downloaded drug responses measured as -log(GI 50 ) for datasets A118. From NCI DTP (12), we downloaded the Metabolon metabolomic dataset, Sequenom DNA methylation dataset, and drug responses for 97 FDA-approved anticancer drugs.
From the mRNA expression data, we inferred co-expression networks using ARACNe (13), CLR (14) , MIRNET (15), C3NET (16) and GENIE3 (17) . In the first three methods, we constructed two networks for each method, using Spearman rank coefficient and mutual information as a relationship measure. From the eight resulting gene coexpression networks, we constructed a single consensus network, by taking edges that were present in all 8 networks, and also edges that were present in at least six networks if the two genes for the edge were significantly positively or negatively correlated at two-tailed p≤0.05 after Bonferroni correction. We repeated the same procedure with phosphoprotein data, arriving with a consensus protein coexpression network.
From the inferred cell-wide protein and gene consensus coexpression networks, we narrowed our focus to networks centered around individual Pathway Activation Scores. Each such network consists of proteins, genes and other entities that were directly correlated with the Score. We calculated Pearson correlation coefficients, with Bonferroni-adjusted two-tailed p=0.05 cut-off, to detect genes (mRNA expression), DNA mutation, methylation and copy number, metabolites and drug sensitivities that are directly correlated with each Pathway Activation Score. For DNA mutation, a dichotomous variable, we measured the point-biserial correlation coefficient. We also detected correlations between the Scores and all individual total, phospho-and cleaved proteins, using a more strict Bonferroni-adjusted p=0.01 cut-off. On top of proteins and genes directly correlated with the Score, we also included their immediate neighbors in the inferred consensus coexpression networks, and any edges between them that existed in those networks.
RESULTS
Pathway Activation Profiling of the NCI-60 Tumor Cell Lines
In order to understand the basal signaling network architecture of the NCI-60 panel, we performed an initial broad-scale protein pathway activation mapping analysis of 194 proteins and phosphoproteins, the largest number measured for the set to-date. The full RPPA dataset can be 
Network Module Construction and Analysis
Based on the pathway-centric nature of the signaling architecture revealed, and in order to more fully interrogate the relationships between phosphorylation-driven signaling at the pathway level and other "-omic" and drug sensitivity relationships, we took advantage of the fact that we measured the activation/phosphorylation of a number of key signaling proteins that spanned specific signaling pathways and developed biochemically-linked signaling "modules" for systems-level analysis. We focused our "pathway module" analyses on six important signal transduction pathways (Table 1) .
Systems Level "-Omic" Analysis
As we defined the module-driven pathway activation states for the NCI-60 cell lines, we sought to understand all the possible relationships between our pathway module activation results and the very large and full complement of publicly available molecular data for the NCI-60 set as well as the individual RPPA-driven phosphoproteomic data we derived. In particular, the Developmental Therapeutics Program (DTP) serves as a vital resource for preclinical information and research materials, including web-accessible data and tools and the molecular analysis and drug sensitivity screening of the NCI-60 tumor cell line, among other information. Thus, we were able to correlate the individual RPPA phosphoprotein and protein data we generated, as well as the pathway activation scores for our six signal transduction networks, to DNA copy number and mutation data, methylation status, mRNA and miRNA expression, along with drug and metabolite responses. From the cell-wide protein and gene consensus coexpression networks, we selected as network nodes all of the genes and proteins that were identified as statistically correlated with the Pathway Activation Score, and linked them to the Pathway Score node ( Figure 3A-B, Supplementary Figure S4) . In the figures, we also included these nodes' direct neighbors in the inferred consensus networks, that is, for each node directly correlated with Pathway Score, we included all genes or proteins linked to that node in the inferred protein and gene coexpression networks, even if they were not significantly correlated with the Pathway Score. We included all edges between the selected nodes in the inferred consensus networks. For all the gene nodes in the resulting Score-centered network, we searched for genes that had significantly correlated DNA mutation, methylation and copy number, as well as for miRNAs with correlated expression, metabolites with correlated levels, and drugs with correlated growth inhibition profiles, and included them in the network. In Figure 3 and Supplementary Figure   S4 , we used different colors to denote different types of analytes (e.g. protein, gene, metabolite, etc.), and used solid or dashed lines to indicate positive or negative correlations, respectively. For the phosphoprotein nodes, we repeated the same search for correlations using the expression of genes encoding these proteins. Also, we looked for direct correlations between phosphoprotein levels and DNA mutation, metabolite levels and drug responses. We did not observe any RPPA endpoints that correlated negatively with pathway score, although some other types of variables (e.g. microRNA expression) with negative correlations were observed. However, the possibility of negative correlations between pathway scores and RPPA endpoints outside the pathway modules technically exists. To account for this possibility, we considered both positive and negative correlations in our analyses, and used two-tailed statistical tests.
We also constructed a unifying joint network ( Figure 3C ), attempting to link all six of the pathway modules together, but in this instance we only included phosphoproteins that were significantly correlated with at least two different Pathway Scores in order to focus on the strongest linkages.
Then, we looked for significant correlations of those phosphoproteins, or of genes encoding them, to DNA mutation, methylation and copy number data, as well as to metabolite and drug data. For all pathway activation modules analyzed, we found that 83% (109/131) of the direct linkages to the central pathway activation score were established by individually RPPA-generated phosphoprotein measurements (brown edges), even though we found correlations with all the other types of data.
Moreover, specific statistically significant linkages were identified between RPPA-generated phosphoproteins and proteins and the other "-omic" data measured (Figure 3 and Supplementary Figure S4 ). 
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To assess drug sensitivity-network correlations, we considered two publicly available drug sensitivity databases: the A118 database and a database comprised of a panel of 97 FDA-approved targeted drugs. The A118 database is composed of 118 of the most common chemotherapeutic drugs in use, and along with the 97 FDA-approved targeted drugs have been tested by DTP on the NCI-60 to evaluate their sensitivity and resistance as defined by LC 50 and GI 50 determinants.
Considering all the networks together, we were able to define both positive (solid line) and negative (dash line) correlations between drug -log(GI 50 )s and several proteins/genes. Focusing on targeted therapies, we found significant correlations with five drugs specifically: imatinib, vemurafenib, sunitinib, nilotinib and crizotinib. Interestingly, when the correlation between a drug sensitivity and a phosphoprotein was positive, the same phosphoprotein was directly and positively correlating as well with the mutation of the gene (and only with that one gene) against which the drug is specific. Because the mechanism of action of nearly all oncology-based therapeutics, especially the new classes of targeted therapeutics, is based largely on the modulation of protein activity/protein expression as the principal drug target, and it is known that cancer is largely driven by disregulated and hyperactivated signaling networks (9, 18), as proteomic technologies have matured, their use in these molecular characterization efforts has become increasingly important. To date, a central missing component of the NCI-60 profiling efforts has been the lack of broad-scale protein activation/phosphorylation analysis. Past integrative biology efforts that incorporated proteomic analysis of the NCI-60 set have either used a more limited number of individual proteins (N=74) (10), compared to our analysis (N=135) for defined drug sensitivity analysis, or evaluated total protein levels in an attempt to link gene and protein expression levels together (and found little concordance between these datasets) (6). Moreover, our own analysis of the total levels and corresponding phosphorylation levels of a number of important cytoplasmic signaling proteins such as ERK, AKT and receptor proteins such as ERBB3 revealed complete lack of concordance (Supplementary Figure S5) , which indicated that direct measurements of the phosphorylation levels of a given analyte are necessary and cannot be inferred from measuring the total levels alone. Most importantly, these past efforts used a one-analyte-at-a-time approach for correlation and integrated analysis, and since we now know that cancer is a pathway-oriented disease (9, 18), we postulated that a more detailed molecular analysis that utilized a network-oriented approach would provide new insights into how different molecular compartments may link together and better characterize drug sensitivity markers. Here, we report the integration of individual protein activation/phosphorylation measurements into biochemically connected pathway modules that provide a new means to align functional protein architecture with multiple "-omic" data sets and therapeutic response correlations.
In this study, we have developed a novel systems biology-based approach to "multi-omic" network analysis through the implementation of a phosphorylation-driven pathway activation score to integrate functional signaling data from RPPA analysis with all other "multi-omic" data.
Orientation of systems biology analysis toward pathway/network focused function instead of individual genes, proteins or phosphoproteins will be a critical next step in translational research.
This network-based approach is useful not only as a new means to integrate genomic, metabolomic, and proteomic data together, but also to delve into the molecular basis through which a drug acts and discover new potential inhibitory mechanisms for drugs with unknown mechanisms of action.
Despite the complex relationships revealed by our analysis (Figure 3, Supplementary Figure S4 The transcription factor RUNX1T1 (together with RUNX1) is known to be involved in several cancers, above all hematopoietic malignancies, due to its repressor activity that involves histone deacetylases and the ability to undergo chromosomal translocation, where the t8;21 is the most well-known, and results in expression of a leukemia-specific chimeric transcription factor (22) . -18a, -19a, -20a, -19b-1, -91a-1 and mir-106b, -93 , -25 respectively, were upregulated in colorectal cancer stromal tissues compared to normal stroma. Gene expression profiles of the same stromal tissue samples revealed that putative targets of these miRNA clusters, such as TGFβR2, SMAD2, and BMP family genes, were significantly downregulated in cancer stromal tissue. Other downregulated putative targets were found to be involved in cytokine interaction and cellular adhesion, strengthening the evidence for involvement of these miRNAs in adhesion, including the integrin pathway (31) . miR-17-92 has been shown to inhibit collagen synthesis by targeting TGFβR2, in mice (32), as well as it is known that miR-93 promotes 
angiogenesis and tumor growth by targeting integrinβ8 (33) , and, together with mir-106a, appears to directly target the Cofilin2 gene (34).
The correlations we found concerning miRNAs within both the integrin and other modules underpin the growing relevance of these regulatory nucleic acids in governing many cellular processes. The ability to identify new miRNA targets could be enhanced by generating a systems-level analysis that could predict new, possible biological correlations using "multi-omic" datasets and bioinformatic tools. Since many investigators are excited by the potential regulatory framework of miRNA and protein expression, orienting connectivity analysis with functional protein network activation as the proximal center could provide a firm basis of such exploration.
We were also able to use our network analysis to identify correlations concerning sensitivity to specific chemotherapeutics and targeted drugs. Of particular interest was the interconnection between phosphoproteins directly connected to the central score with targeted drugs and the mutation of the gene encoding the drug target. As stated previously, we found both positive and negative correlations with five targeted therapeutics: imatinib, vemurafenib, sunitinib, nilotinib and crizotinib. When these drugs had positive correlations with the gene or the phosphoprotein encoded by the gene, the same phosphoprotein was also positively correlated with the mutated gene targeted by that drug. For example, phospho-Pyk2 or phospho-STAT5 correlated with both imatinib and mutated PDGFRα. Also, phospho-p90RSK correlated with vemurafenib and the mutation of B-RAF ( Figure 3A-B and Supplementary Figure S4) . Of course, in vitro experiments are needed to study the cellular responses to these drugs, and to further confirm the existence of biological effects involving our predicted phosphoprotein-driven networks. This approach may provide a deeper understanding of how cellular biochemistry defines therapeutic response. Such "-omic" portraits could inform rational anticancer agent screenings and drive personalized therapeutic approaches. There are certainly limitations to our current study. Due to the complexity of cell signaling and the large volume of data we integrated, we cannot simply assume that the connections we found are all clinical relevant and many likely do not occur in every patient/tumor. A critical problem for systems-level analysis of large datasets is the over-fitting of the data. By using a network/signaling module-based approach, which we feel more accurately reflects the signaling architecture, we hope to minimize inaccurate conclusions since our analysis uses this as the central hub of the network and works outward. Any interconnections, however, would need to be extensively validated and verified. We also utilized statistical approaches that minimize overfitting, but these efforts can only dampen chances of random associations being found, not eliminate them. We could verify the correctness of these models, such as the consistent connections of the Hippo family, with in vitro chemical and genomic knock-out analysis, as well as expanding our phosphoproteomic analysis to include other proteins that were not considered in the first experimental design but could be tied to these specific networks. Our approach was based on a "hub" model philosophy whereby we chose broad-scale analyses centered on interrogating signaling proteins known to be integration points within the signaling architecture, under the postulate that even with incomplete coverage, we would be measuring the aggregate signaling inputs and outputs of a larger series of proteins. By aggregating these individual protein nodes with upstream and downstream direct first-order kinasesubstrate relationships, we generate more complete data about the true nature of the signaling activation state rather than just an assortment of phosphoproteins randomly distributed across the kinase space. Moreover, our analysis is based solely on data from a limited number of cell lines, which most certainly do not recapitulate the heterogeneous state of human cancer in vivo, nor are representative of all of the cancer cell line sets in the public domain. Lastly, despite the broad-scale pathway activation mapping performed, the totality of the kinome and signaling architecture was not queried and the networks chosen for exploration while important to cancer biology and therapy were not comprehensive to include every known pathway and drug target. Thus, we present this data as both a guide to future "-omic" analyses as well as first steps into a protein network-centered journey into future analyses rather than as a definitive dataset.
In conclusion, we utilized a novel, functional network-oriented approach that incorporated the most comprehensive protein pathway activation mapping analysis performed to date on the NCI-60 cell line set in order to interrogate connectivity with other "-omic" data previously generated. Inclusion of the phosphoprotein data in the public domain as a growing information archive and knowledge base will provide an expanding opportunity for a systems biology view of tumorigenesis and related biology, cell line sets such as the NCI-60 provide a unique opportunity to investigate molecular correlations tied to causality within the defined context of the system used. Coupling extensive molecular architecture surrounding the genome, proteome, phosphoproteome, metabolome, and other molecular archives with drug sensitivity screens provide a unique "sandbox" to exploit the aggregate efforts of hundreds of scientists to more fully understand cancer biology. In the future, we hope that our pathway-oriented approach can generate new data concerning optimal therapeutic combinations, identify new predictive markers for therapeutic efficacy and uncover new insights about how intra-and intercellular communications occur. 
